UBS Group upgraded shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) to a hold rating in a report issued on Sunday,Zacks reports. Several other brokerages also recently issued reports on MLYS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. HC Wainwright reiterated a “buy” […]

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports. A number of other equities analysts have also recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of Protagonist […]

Odyssey Therapeutics (NASDAQ:ODTX – Get Free Report) was upgraded by analysts at UBS Group to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks reports. Several other research firms have also recently issued reports on ODTX. Oppenheimer reissued an “outperform” rating and set a $40.00 price target on shares […]

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) was upgraded by research analysts at UBS Group to a “hold” rating in a report released on Sunday, Zacks reports. MLYS has been the subject of several other research reports. HC Wainwright reaffirmed a “buy” rating and set a $56.00 price target on shares of Mineralys Therapeutics in […]